GEN Exclusives

More »

GEN News Highlights

More »
Nov 21, 2006

Actavis Enlarges Russian Presence

  • Actavis acquired a 51% controlling interest in ZiO Zdorovje, a Russian pharmaceutical manufacturer.
    Out of a total cost of $60 million for the deal, $30 million will be targeted for investment in the ZiO Zdorovje manufacturing site with the goals of creating a platform for increased production and capacity as well as introducing new products.

    The current owners of ZiO Zdorovje will retain a 49% stake in the business.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?